4-hydroxypraziquantel: metabolite of praziquantel; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 173759 |
| CHEMBL ID | 1470 |
| MeSH ID | M0185109 |
| Synonym |
|---|
| 4-hydroxypraziquantel |
| CHEMBL1470 |
| trans-hydroxy praziquantel |
| cis-hydroxy praziquantel |
| 2-(4-hydroxycyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4-one |
| 134924-68-8 |
| 4h-pyrazino(2,1-a)isoquinolin-4-one, 1,2,3,6,7,11b-hexahydro-2-((cis-4-hydroxycyclohexyl)carbonyl)- |
| 134924-71-3 |
| 4h-pyrazino(2,1-a)isoquinolin-4-one, 1,2,3,6,7,11b-hexahydro-2-((trans-4-hydroxycyclohexyl)carbonyl)- |
| 60743-58-0 |
| 4h-pyrazino(2,1-a)isoquinolin-4-one, 1,2,3,6,7,11b-hexahydro-2-((4-hydroxycyclohexyl)carbonyl)- |
| unii-s76zx3n3lf |
| s76zx3n3lf , |
| FT-0670039 |
| FT-0670038 |
| 2-(4-trans-hydroxycyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino[2,1-a]isoquinolin-4-one |
| SY233691 |
| mfcd31630431 |
| 2-(4-hydroxycyclohexanecarbonyl)-2,3,6,7-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4(11bh)-one |
| 2{4-hydroxy-cyclohexanecarbonyl)-4-oxo-1,2,3,6,7,11b-hexahydro-4h-pyrazino [2,1-a]isoquinoline |
| DTXSID10928822 |
| 2-(4-hydroxycyclohexane-1-carbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino[2,1-a]isoquinolin-4-one |
| rac-hydroxy praziquantle impurity |
| 1,2,3,6,7,11b-hexahydro-2-[(cis-4-hydroxycyclohexyl)carbonyl]-4h-pyrazino[2,1-a]isoquinolin-4-one; trans-1,2,3,6,7,11b-hexahydro-2-[(4-hydroxycyclohexyl)carbonyl]- 4h-pyrazino[2,1-a]isoquinolin-4-one |
| (3,10a-diaza-2,3,4,4a,9,10-hexahydrophenanthr-3-oyl)(4-hydroxycyclohexyl)formaldehyde |
| 1,2,3,6,7,11b-hexahydro-2-[(cis-4-hydroxycyclohexyl)carbonyl]-4h-pyrazino[2,1-a]isoquinolin-4-one; cis-(+/-)-1,2,3,6,7,11b-hexahydro-2-[(4-hydroxycyclohexyl)carbonyl]- 4h-pyrazino[2,1-a]isoquinolin-4-one |
| AC1421 |
| 1,2,3,6,7,11b-hexahydro-2-[(trans-4-hydroxycyclohexyl)carbonyl]-4h-pyrazino[2,1-a]isoquinolin-4-one |
| DTXSID901114356 |
| AKOS037630852 |
| A913603 |
| 4-hydroxycyclohexylcarboxylate |
| 1,2,3,6,7,11b-hexahydro-2-((4-hydroxycyclohexyl)carbonyl)-4h-pyrazino(2,1-a)isoquinolin-4-one |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID299629 | Antischistosomal activity against Schistosoma mansoni assessed as complete spastic paralysis | 2007 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15 | Praziquantel derivatives I: Modification of the aromatic ring. |
| AID299630 | Antischistosomal activity against Schistosoma mansoni assessed as shcistomes paralysis relative to Praziquantel | 2007 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15 | Praziquantel derivatives I: Modification of the aromatic ring. |
| AID299628 | Antischistosomal activity against Schistosoma mansoni assessed as 100% killing of shcistomes relative to Praziquantel | 2007 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15 | Praziquantel derivatives I: Modification of the aromatic ring. |
| AID299627 | Antischistosomal activity against Schistosoma mansoni assessed as 100% killing of schistosomes | 2007 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15 | Praziquantel derivatives I: Modification of the aromatic ring. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||